SCHEMBL3391014

SCHEMBL3391014

O=C(O)CNC(=O)c1ccc[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.58
KEAP1 Q14145 1/20 0.50
TYK2 P29597 1/20 0.49
SMYD3 Q9H7B4 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 1/20 0.45
EGLN1 Q9GZT9 4/20 0.43
PARP1 P09874 1/20 0.43
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
HIF1A Q16665 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18985201 0.82 GAA (0.59) NAPRTKEAP1RAB9AEGLN1KDM4E
SCHEMBL109595 0.79 NAPRT (0.60) NAPRTTYK2SMYD3RAB9ANPC1
SCHEMBL16982383 0.79 NAPRT (0.51) NAPRTTYK2SMYD3RAB9ANPC1
SCHEMBL31448014 0.78 KEAP1 (0.62) KEAP1RAB9AEGLN1KDM4EMAPT
SCHEMBL5815105 0.78 HPGD (0.56) NAPRTTYK2SMYD3RAB9AMAPT
SCHEMBL19723122 0.78 NAPRT (0.50) NAPRTTYK2SMYD3RAB9ANPC1
SCHEMBL3242636 0.77 KDM4E (0.55) KDM4EMEN1POLBKMT2A
SCHEMBL6916843 0.77 NAPRT (0.62) NAPRTTYK2SMYD3RAB9ANPC1
SCHEMBL1663526 0.75 NAPRT (0.60) NAPRTTYK2SMYD3RAB9ANPC1
SCHEMBL3368022 0.75 TYK2 (0.70) NAPRTTYK2RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION FIBROGEN, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION NFATC1, CD4, IL2 NAPRT 2146/4885KEAP1 1697/4885TYK2 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.